First Trust NASDAQ Clean Edge Green Energy Idx Fd vs GeneDx Holdings Corp — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.03, while GeneDx Holdings Corp trades at $62.68 (market cap $1.83B). The key difference: First Trust NASDAQ Clean Edge Green Energy Idx Fd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| QCLN | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $68.47 | $167.51 |
52-Week Low | $34.31 | $34.51 |
Market Cap | — | $1.83B |
Enterprise Value | — | $1.83B |
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $51.25, down 1.9% with a bearish technical signal showing 17 sell indicators versus 3 buy signals. The ETF faces headwinds from regulatory uncertainty around renewable energy permits and supply chain pressures, though long-term growth prospects remain supported by rising data center energy demand and global clean energy investments. Technical analysis indicates strong resistance at $52-$56 with support at $48-$51.
The clean energy sector faces near-term policy risks but benefits from structural tailwinds. Investment appeal depends on resolution of US permit delays and China trade tensions, with current technical weakness suggesting cautious entry points may emerge near support levels for long-term positioning in the energy transition theme.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Trailing returns across standard periods
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →